MedPage Today on MSN
Paradigm Shift for Evaluating, Treating Biochemical Recurrence in Prostate Cancer
When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...
UCLA researchers found that routine PSMA PET/CT scans could help doctors select treatment approaches for the best long-term outcomes in patients with recurring prostate cancer after surgical removal ...
A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...
Until recently, the treatment of metastatic castration-resistant prostate cancer (mCRPC) relied exclusively on hormonal therapies and taxane chemotherapy. The advent of modern molecular profiling ...
SurvivorNet on MSN
Prostate cancer screening: Get the actual guidelines for men, why doctors don’t agree, and what you need to know to make decisions
A new Super Bowl Sunday ad starring legendary NFL players aims to boost prostate cancer awareness. Using humor and famous ...
In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer. In a recent interview with CURE, Dr. Kai Tsao broke down current treatment ...
Please provide your email address to receive an email when new articles are posted on . Researchers at The Ohio State University have harnessed artificial intelligence machine learning processes to ...
Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results